The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | Identification of high-risk disease using Molecular profiling by Mymap
Gareth Morgan, MD, FRCP, FRCPath, PhD from the University of Arkansas for Medical Sciences, Arkansas, AR talks about gene expression analysis in multiple myeloma (MM), which can help determine the prognosis of the disease based on different molecular sub-groups. The Arkansas group has developed a simple test that can help identify the genetic markers of high-risk MM, called Mymap. The data was presented at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.
